Skip to main content

Table 4 Surface marker expression of DC 6 days after culture from PBMCs

From: A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment

Marker HLA-DR CD86 CD40
Patient
1 93.39a 96.47 98.22
2 95.4 85.36 99.41
3 83.14 94.17 95.51
4 95.2 94.98 96.64
5 97.92 93.64 98.96
6 95.98 87.72 94.75
7 84.4 93.08 97.24
8 86.25 95.35 99.18
9 94.03 96.22 94.54
10 90.67 93.29 97.71
11 89.52 97.43 98.25
12 95.9 93.76 95.97
Mean ± SD 91.8 ± 4.96 93.5 ± 5.34 97.2 ± 1.71
  1. aResults were expressed as the percentage of cells stained positive for a given mAb